<DOC>
	<DOCNO>NCT00087763</DOCNO>
	<brief_summary>The purpose study determine Macugenâ„¢ reduce foveal thickness improve vision patient wet AMD .</brief_summary>
	<brief_title>Pegaptanib Sodium Foveal Thickening Patients With Exudative Subfoveal Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>This randomize , double-masked , control , dose-ranging , multi-center comparative trial , parallel group . Patients stratify clinical center foveal thickness treat either Macugen sham injection . After 24 week , patient treat Macugen end study 54 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity study eye 20/40 20/320 good equal 20/800 fellow eye . Foveal thickness &lt; = 300 um ( measure OCT center point thickness ) . Subfoveal choroidal neovascularization secondary agerelated macular degeneration , total lesion size ( include blood , scar/atrophy &amp; neovascularization ) &lt; = 12 disc area , least 50 % must active CNV . Previous subfoveal thermal laser therapy . Any subfoveal atrophy scarring , blood fovea , fibrosis . Additionally 25 % total lesion size may make scar atrophy . Previous photodynamic therapy Visudyne ( PDT ) study eye . Eyes predominantly classic lesion ( classified fluorescein angiographic appearance ) may enrol trial , clinical judgment investigator , PDT defer least 54 week first study treatment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>Exudative Subfoveal Age Related Macular Degeneration Subfoveal Choroidal Neovascularization</keyword>
</DOC>